Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
VENTOGRAFT study of venetoclax + azacitidine + donor lymphocyte infusion after allo-HSCT relapse
2024-514877-23-00Phase 2Authorised
- Sponsor
- Groupe Français des Myélodysplasies
- Start
- Oct 2024
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of venetoclax and azacitidine in myelodysplastic syndrome (MDS) and acute myeloid leukemia (AML), sponsored by Groupe Français des Myélodysplasies. Primary endpoints: Phase I safety and toxicity profile and Phase II overall hematological response rate. Planned start Oct 2024; status: authorised.
02
Drugs
venetoclaxazacitidine
03
Conditions
myelodysplastic syndrome (MDS)acute myeloid leukemia (AML)
Beyond the preview
Go deeper on 2024-514877-23-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-514877-23-00.